PODD Stock Recent News

Insulet Corporation (NASDAQ:PODD ) Baird Global Healthcare Conference 2025 September 9, 2025 12:15 PM EDT Company Participants Eric Benjamin - Executive VP & COO Ana Chadwick - Executive VP & CFO Conference Call Participants Jeffrey Johnson - Robert W. Baird & Co. Incorporated, Research Division Presentation Jeffrey Johnson Senior Research Analyst Jeff Johnson.

Insulet Corporation (NASDAQ:PODD ) Wells Fargo 20th Annual Healthcare Conference 2025 September 4, 2025 3:00 PM EDT Company Participants Ashley McEvoy - CEO, President & Director Ana Chadwick - Executive VP & CFO Conference Call Participants Larry Biegelsen - Wells Fargo Securities, LLC, Research Division Presentation Larry Biegelsen Senior Medical Device Equity Research Analyst All right. Welcome back.

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced the appointment of Eric Benjamin to Chief Operating Officer effective immediately. The Company also announced the appointment of Manoj Raghunandanan as Chief Growth Officer. In this expanded role, Mr. Benjamin will lead Insulet's end-to-end growth and innovation engine, setting strategy and guiding.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

PODD's 77.2% stock surge is fueled by Omnipod 5 expansion, global launches, strong Q2 profits and robust financial stability.

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management will present at the upcoming investor conferences (all Eastern Time): Wells Fargo 2025 Healthcare Conference in Boston on September 4 at 3:00 p.m. Baird 2025 Global Healthcare Conference in New York City on September 9 at 12:15 p.m. Bernstein Insights: Healthcare Leaders & Disruptors Forum in New York Ci.

PODD delivered strong Q2 results, exceeding revenue guidance, improving gross margin, and launching the Omnipod 5 iPhone app, strengthening its ecosystem position. Omnipod 5's pharmacy channel penetration and positive clinical data support sustained >20% annual revenue growth and margin expansion over the next 3-5 years. The market underestimates the long-term impact of pharmacy distribution, which reduces onboarding friction, broadens payer access, and improves retention economics.

PODD posts strong Q2 earnings and revenues and lifts its 2025 outlook, marking a decade of 20%+ constant-currency growth.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Insulet Corporation  PODD reported second-quarter adjusted earnings of $1.17 per share, beating the consensus of 92 cents.